Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical SurveyDefense World · 5 days ago
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research · 5 days ago
Intellia Therapeutics Appoints Jing L. Marantz, M.D.GlobeNewsWire · Oct 13, 2026
Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)Defense World · Oct 12, 2026
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Zacks Investment Research · Oct 9, 2026
Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at BarclaysDefense World · Oct 8, 2026Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.80 | -$0.80 | Miss |
| May 11, 2026 | -$0.92 | -$0.81 | Beat |
| Feb 26, 2026 | -$0.99 | -$0.83 | Beat |
| Nov 6, 2025 | -$1.02 | -$0.92 | Beat |
| Aug 7, 2025 | -$1.03 | -$0.99 | Beat |
| May 8, 2025 | -$1.26 | -$1.10 | Beat |